RxDoctor Payments Data

Daniel Lustgarten

Cardiovascular Disease · Burlington, VTNPI 1659398501

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $67,932, 2.2 times the $30,273 reported in 2019. Among cardiovascular disease clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$170,598in general payments, 2019–2025

Across 173 payments — averaging $986.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$115K
  • Abbott$33K
  • Boston Scientific$22K
  • Biotronik Inc.$1K
$1,030,685in research payments, 2019–2025

Across 149 payments — averaging $6917.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$792K
  • Abbott$221K
  • Boston Scientific$15K
  • Biotronik Inc.$3K

What the payments were for

  • Consulting fees$61,59636%
  • Speaking & faculty fees$98,40058%
  • Travel & lodging$5,3503%
  • Food & beverage$4,6343%
  • Education$6180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)115$114,662
Abbott48$32,593
Boston Scientific7$22,130
Biotronik Inc.3$1,213

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,598 in reported general payments places this provider in the 95th percentile of 27 cardiovascular disease providers in Vermont.

See all cardiovascular disease providers in Vermont

Medicare billing

Part B allowed, 2024
$154,477
Medicare patients
1,656
Services billed
2,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$309,324
XareltoRivaroxaban73$101,953
Dofetilide224$59,800
Diltiazem 24hr Er (Cd)Diltiazem Hcl114$3,051
Diltiazem 24hr Er (La)Diltiazem Hcl13$1,750
Flecainide Acetate17$1,215
Metoprolol Succinate43$909
Torsemide28$851
ClopidogrelClopidogrel Bisulfate85$816
Dilt-XrDiltiazem Hcl14$668
Amiodarone Hcl31$657
Diltiazem Hcl39$597
Diltiazem 24hr ErDiltiazem Hcl16$541
Atorvastatin Calcium20$277
Losartan Potassium14$185

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →